These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19627235)

  • 41. Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial.
    Haidari G; Cope A; Miller A; Venables S; Yan C; Ridgers H; Reijonen K; Hannaman D; Spentzou A; Hayes P; Bouliotis G; Vogt A; Joseph S; Combadiere B; McCormack S; Shattock RJ
    Sci Rep; 2017 Oct; 7(1):13011. PubMed ID: 29026141
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
    Sekaly RP
    J Exp Med; 2008 Jan; 205(1):7-12. PubMed ID: 18195078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DNA vaccines and intradermal vaccination by DNA tattooing.
    Oosterhuis K; van den Berg JH; Schumacher TN; Haanen JB
    Curr Top Microbiol Immunol; 2012; 351():221-50. PubMed ID: 21107792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation.
    Liu J; Kjeken R; Mathiesen I; Barouch DH
    J Virol; 2008 Jun; 82(11):5643-9. PubMed ID: 18353952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BTX AgilePulse(TM) system is an effective electroporation device for intramuscular and intradermal delivery of DNA vaccine.
    Davtyan H; Hovakimyan A; Zagorski K; Davtyan A; Petrushina I; Agdashian D; Murthy V; Cribbs DH; Agadjanyan MG; Ghochikyan A
    Curr Gene Ther; 2014; 14(3):190-9. PubMed ID: 24867066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccine development against HIV-1: current perspectives and future directions.
    Edgeworth RL; San JH; Rosenzweig JA; Nguyen NL; Boyer JD; Ugen KE
    Immunol Res; 2002; 25(1):53-74. PubMed ID: 11868934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device.
    Amante DH; Smith TR; Mendoza JM; Schultheis K; McCoy JR; Khan AS; Sardesai NY; Broderick KE
    Hum Gene Ther Methods; 2015 Aug; 26(4):134-46. PubMed ID: 26222896
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration.
    Chiarella P; Massi E; De Robertis M; Sibilio A; Parrella P; Fazio VM; Signori E
    Expert Opin Biol Ther; 2008 Nov; 8(11):1645-57. PubMed ID: 18847301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful vaccination of immune suppressed recipients using Listeria vector HIV-1 vaccines in helminth infected mice.
    Shollenberger LM; Bui C; Paterson Y; Allen K; Harn D
    Vaccine; 2013 Apr; 31(16):2050-6. PubMed ID: 23470236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The potential of topical DNA vaccines adjuvanted by cytokines.
    Lisziewicz J; Calarota SA; Lori F
    Expert Opin Biol Ther; 2007 Oct; 7(10):1563-74. PubMed ID: 17916048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SPIRAT group begins clinical trial of DNA-based therapeutic vaccine. Strategic Program for Innovative Research on AIDS Treatment.
    Folkers G
    NIAID AIDS Agenda; 1995 Sep; ():2. PubMed ID: 11362801
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adipose tissue: a new target for electroporation-enhanced DNA vaccines.
    Fisher PD; Brambila CJ; McCoy JR; Kiosses WB; Mendoza JM; Oh J; Yung BS; Schultheis K; Smith TRF; Broderick KE
    Gene Ther; 2017 Dec; 24(12):757-767. PubMed ID: 29106403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Viral vectors as potential HIV-1 vaccines.
    Schnell MJ
    FEMS Microbiol Lett; 2001 Jun; 200(2):123-9. PubMed ID: 11425463
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome research.
    Fischer E; Rieux V; Guillet JG; Kazatchkine M
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):79-84. PubMed ID: 15867969
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Needle-free topical electroporation improves gene expression from plasmids administered in porcine skin.
    Babiuk S; Baca-Estrada ME; Foldvari M; Baizer L; Stout R; Storms M; Rabussay D; Widera G; Babiuk L
    Mol Ther; 2003 Dec; 8(6):992-8. PubMed ID: 14664802
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates.
    Dharmapuri S; Peruzzi D; Mennuni C; Calvaruso F; Giampaoli S; Barbato G; Kandimalla ER; Agrawal S; Scarselli E; Mesiti G; Ciliberto G; La Monica N; Aurisicchio L
    Mol Ther; 2009 Oct; 17(10):1804-13. PubMed ID: 19623161
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation.
    Mendoza JM; Amante DH; Kichaev G; Knott CL; Kiosses WB; Smith TR; Sardesai NY; Broderick KE
    Vaccines (Basel); 2013 Aug; 1(3):384-97. PubMed ID: 26344120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimization of In Vivo Electroporation Conditions and Delivery of DNA Vaccine Encoding SARS-CoV-2 RBD Using the Determined Protocol.
    Kisakov DN; Kisakova LA; Borgoyakova MB; Starostina EV; Taranov OS; Ivleva EK; Pyankov OV; Zaykovskaya AV; Shcherbakov DN; Rudometov AP; Rudometova NB; Volkova NV; Gureev VN; Ilyichev AA; Karpenko LI
    Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365078
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improving DNA vaccine performance through vector design.
    Williams JA
    Curr Gene Ther; 2014; 14(3):170-89. PubMed ID: 25142448
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV-1 vaccine candidate evaluation in non-human primates.
    Lu Y
    Crit Rev Oncog; 1997; 8(2-3):273-91. PubMed ID: 9570296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.